uniQure

ISIN NL0010696654

 | 

WKN A1XDTV

Market cap (in EUR)
1,346 m
Country
Netherlands
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Netherlands

Financials

Key metrics

Market capitalisation, EUR 1,346 m
EPS, EUR -3.97
P/B ratio 6.9
P/E ratio -
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 25 m
Net income, EUR -221 m
Profit margin -883.35%

What ETF is uniQure in?

There are 4 ETFs which contain uniQure. All of these ETFs are listed in the table below. The ETF with the largest weighting of uniQure is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
JPMorgan Active US Growth UCITS ETF USD (acc) 0.05%
Equity
United States
Growth
359
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.32%
Equity
United States
Health Care
Biotech
44
JPMorgan Active US Growth UCITS ETF USD (dist) 0.05%
Equity
United States
Growth
1
JPMorgan Active US Growth UCITS ETF EUR Hedged (acc) 0.05%
Equity
United States
Growth
9
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.